Letter to the Editor Open Access
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virol. Jul 25, 2022; 11(4): 204-207
Published online Jul 25, 2022. doi: 10.5501/wjv.v11.i4.204
Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy
Tarun Sahu, Physiology, All India Institute of Medical Science, Raipur 492001, Chhattisgarh, India
Henu Kumar Verma, Department of Immunopathology, Institute of Lung Health and Immunity, Comprehensive Pneumology Center, Helmholtz Zentrum, Munich 80331, Bayren, Germany
Bhaskar Lvks, Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur 495001, Chhattisgarh, India
ORCID number: Tarun Sahu (0000-0002-2721-7432); Henu Kumar Verma (0000-0003-1130-8783); Bhaskar Lvks (0000-0003-2977-6454).
Author contributions: Sahu T, Verma HK, Lvks B wrote and revised the letter.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Henu Kumar Verma, PhD, Research Scientist, Department of Immunopathology, Institute of Lung Health and Immunity, Comprehensive Pneumology Center, Helmholtz Zentrum, Ingolstädter Landstrasse 1, Munich 80331, Bayren, Germany, henu.verma@yahoo.com
Received: June 5, 2021
Peer-review started: June 5, 2021
First decision: July 27, 2021
Revised: July 28, 2021
Accepted: May 27, 2022
Article in press: May 27, 2022
Published online: July 25, 2022
Processing time: 411 Days and 10.8 Hours

Abstract

Patients with lymphoid malignancies are at a higher risk of coronavirus disease 2019 (COVID-19) infection due to their immunocompromised state and results in higher mortality rates in these patients. Anti-CD 20 therapy is one of the leading causes of immunosuppression that worsens in COVID-19 cases. COVID-19 vaccines, on the other hand, appear to be less beneficial to these patients. App-ropriate treatment and recommendations are required for these COVID-19 patients with lymphoid malignancies.

Key Words: COVID-19; Lymphoid malignancy; Lymphoma; Vaccination; Immuno-suppression

Core Tip: Patients with hematologic conditions are two times more likely than others to be admitted to the hospital. They are being treated with anti-cancer drugs, which weakens their immune system. As a result, these patients are always at risk of coronavirus disease 2019 (COVID-19). As we know, the COVID-19 is very lethal, and hematological malignancies are likely to increase the risk of negative outcomes from this viral infection. Currently, there are no guidelines for treating COVID-19 infected patients with hematological malignancies.



TO THE EDITOR

In March 2019, the World Health Organization declared the novel coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2, as a pandemic. Nearly one-third of patients with lymphoid malignancies experienced severe complications of COVID-19 and required hospitalization[1,2]. According to the 2017 World Health Organization classification, there are more than 80 different types of mature lymphoma, which are divided into three major categories: B-cell neoplasms, T-cell and natural killer cell neoplasms, and Hodgkin lymphomas[3]. We recently read the paper from Riches[4] entitled “Impact of COVID-19 in patients with lymphoid malignancies” in your prestigious journal “World Journal of Virology”. I sincerely thank the author for providing vital information about the effect of COVID-19 in patients with lymphoid malignancies.

Patients with lymphoid malignancies are highly susceptible to COVID-19 infection because they are already immunocompromised due to active cancer treatments. In this review article, the author mainly focused on the impact of COVID-19 on chronic lymphocytic leukemia, which is the most common form of leukemia in western countries[5]. In the present article the author included case studies, cohort studies, systematic reviews, and meta-analyses. Several lines of evidence suggested that the type of hematological malignancy and target antineoplastic therapy, older age, and various preexisting conditions such as hypertension and diabetes are all linked to mortality in lymphoma patients[6-8]. A retrospective study of 343 patients with hematologic malignancies and hematopoietic stem cell transplantation found that severe acute respiratory syndrome coronavirus 2 infection progressed to pneumonia in 119 patients (35%), including those with leukemia, those over the age of 65 years, and those with severe neutropenia or lymphopenia. It also found that more than 85% of patients with lymphoid malignancies required hospital admission, with 9% admitted to the intensive care unit and an overall mortality rate of 34.5%[9].

The information available on the effects of COVID-19 in patients with various hematologic diseases is limited. A series of case reports of COVID-19 patients with various hematological malignancies increases the risk of adverse complications due to immunosuppression caused by the underlying cancer and treatment effects[10-13].

The author does not have much data to show the impact of lymphoma on COVID-19 vaccination at the time of writing his paper. In this context, we would like to mention two recent studies that analyzed the efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia and multiple myeloma. According to these studies, BNT162b2 mRNA COVID-19 vaccine negatively affects the production of neutralizing antibodies in patients treated with anti-chronic lymphocytic leukemia and anti-myeloma therapies[14-16]. As hematologic malignancies are life-threatening conditions and the majority of the medications are immunosuppressive agents that progress to the severe/critical stage and collapse of patients, data for medications in these conditions with COVID-19 are limited[17,18]. To avoid severe conditions and death, researchers/clinicians must develop an appropriate medication guideline for lymphoma patients infected with COVID-19. Percival et al[19] compiled a list of treatment recommendations for patients with hematologic malignancies during the COVID-19 pandemic. Further, more trials on COVID-19 vaccines on these patients should be done along with current therapies of hematologic disease to reveal the appropriate therapies in which these vaccines are effective.

Footnotes

Provenance and peer review: Invited article; Externally peer reviewed

Peer-review model: Single blind

Specialty type: Virology

Country/Territory of origin: Germany

Peer-review report’s scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): D

Grade E (Poor): 0

P-Reviewer: Riches JC, United Kingdom; Sageena G, India; Sivanand N, India A-Editor: Ma L, United States S-Editor: Wang JJ L-Editor: Filipodia P-Editor: Wang JJ

References
1.  Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, Angelucci E, Krampera M, Cairoli R, Della Porta MG, Fracchiolla N, Ladetto M, Gambacorti Passerini C, Salvini M, Marchetti M, Lemoli R, Molteni A, Busca A, Cuneo A, Romano A, Giuliani N, Galimberti S, Corso A, Morotti A, Falini B, Billio A, Gherlinzoni F, Visani G, Tisi MC, Tafuri A, Tosi P, Lanza F, Massaia M, Turrini M, Ferrara F, Gurrieri C, Vallisa D, Martelli M, Derenzini E, Guarini A, Conconi A, Cuccaro A, Cudillo L, Russo D, Ciambelli F, Scattolin AM, Luppi M, Selleri C, Ortu La Barbera E, Ferrandina C, Di Renzo N, Olivieri A, Bocchia M, Gentile M, Marchesi F, Musto P, Federici AB, Candoni A, Venditti A, Fava C, Pinto A, Galieni P, Rigacci L, Armiento D, Pane F, Oberti M, Zappasodi P, Visco C, Franchi M, Grossi PA, Bertù L, Corrao G, Pagano L, Corradini P; ITA-HEMA-COV Investigators. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737-e745.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 373]  [Cited by in F6Publishing: 386]  [Article Influence: 96.5]  [Reference Citation Analysis (0)]
2.  Sahu T, Mehta A, Ratre YK, Jaiswal A, Vishvakarma NK, Bhaskar LVKS, Verma HK. Current understanding of the impact of COVID-19 on gastrointestinal disease: Challenges and openings. World J Gastroenterol. 2021;27:449-469.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in CrossRef: 18]  [Cited by in F6Publishing: 15]  [Article Influence: 5.0]  [Reference Citation Analysis (0)]
3.  de Leval L, Jaffe ES. Lymphoma Classification. Cancer J. 2020;26:176-185.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 25]  [Cited by in F6Publishing: 60]  [Article Influence: 20.0]  [Reference Citation Analysis (0)]
4.  Riches JC. Impact of COVID-19 in patients with lymphoid malignancies. World J Virol. 2021;10:97-110.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in CrossRef: 10]  [Cited by in F6Publishing: 7]  [Article Influence: 2.3]  [Reference Citation Analysis (1)]
5.  Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92:946-965.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 172]  [Cited by in F6Publishing: 193]  [Article Influence: 27.6]  [Reference Citation Analysis (0)]
6.  Lee LY, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, Chackathayil J, Cheng VW, Curley HM, Fittall MW, Freeman-Mills L, Gennatas S, Goel A, Hartley S, Hughes DJ, Kerr D, Lee AJ, Lee RJ, McGrath SE, Middleton CP, Murugaesu N, Newsom-Davis T, Okines AF, Olsson-Brown AC, Palles C, Pan Y, Pettengell R, Powles T, Protheroe EA, Purshouse K, Sharma-Oates A, Sivakumar S, Smith AJ, Starkey T, Turnbull CD, Várnai C, Yousaf N; UK Coronavirus Monitoring Project Team, Kerr R, Middleton G. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395:1919-1926.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 805]  [Cited by in F6Publishing: 801]  [Article Influence: 200.3]  [Reference Citation Analysis (0)]
7.  Shah V, Ko Ko T, Zuckerman M, Vidler J, Sharif S, Mehra V, Gandhi S, Kuhnl A, Yallop D, Avenoso D, Rice C, Sanderson R, Sarma A, Marsh J, de Lavallade H, Krishnamurthy P, Patten P, Benjamin R, Potter V, Ceesay MM, Mufti GJ, Norton S, Pagliuca A, Galloway J, Kulasekararaj AG. Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience. Br J Haematol. 2020;190:e279-e282.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 63]  [Cited by in F6Publishing: 65]  [Article Influence: 16.3]  [Reference Citation Analysis (0)]
8.  Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, Martín-Moro F, Razanamahery J, Riches JC, Zwicker J, Patell R, Vekemans MC, Scarfò L, Chatzikonstantinou T, Yildiz H, Lattenist R, Mantzaris I, Wood WA, Hicks LK. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136:2881-2892.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 483]  [Cited by in F6Publishing: 448]  [Article Influence: 112.0]  [Reference Citation Analysis (0)]
9.  Regalado-Artamendi I, Jiménez-Ubieto A, Hernández-Rivas JÁ, Navarro B, Núñez L, Alaez C, Córdoba R, Peñalver FJ, Cannata J, Estival P, Quiroz-Cervantes K, Riaza Grau R, Velasco A, Martos R, Domingo-González A, Benito-Parra L, Gómez-Sanz E, López-Jiménez J, Matilla A, Herraez MR, Penalva MJ, García-Suárez J, Díez-Martín JL, Bastos-Oreiro M. Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study. Hemasphere. 2021;5:e538.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 28]  [Cited by in F6Publishing: 37]  [Article Influence: 12.3]  [Reference Citation Analysis (0)]
10.  Hoffmann MS, Ganguly S. Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy. Clin Lymphoma Myeloma Leuk. 2021;21:e548-e550.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Cited by in F6Publishing: 8]  [Article Influence: 2.7]  [Reference Citation Analysis (0)]
11.  Yonal-Hindilerden I, Hindilerden F, Mastanzade M, Tiryaki TO, Tasan-Yenigun S, Bilen Y, Aksoz S, Cagatay AA, Nalcaci M. Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin's Lymphoma. Front Oncol. 2021;11:601709.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3]  [Cited by in F6Publishing: 4]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
12.  Jin XH, Zheng KI, Pan KH, Xie YP, Zheng MH. COVID-19 in a patient with chronic lymphocytic leukaemia. Lancet Haematol. 2020;7:e351-e352.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 52]  [Cited by in F6Publishing: 58]  [Article Influence: 14.5]  [Reference Citation Analysis (0)]
13.  Zhang X, Song K, Tong F, Fei M, Guo H, Lu Z, Wang J, Zheng C. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 2020;4:1307-1310.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 186]  [Cited by in F6Publishing: 178]  [Article Influence: 44.5]  [Reference Citation Analysis (0)]
14.  Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, Morales M, Ziv T, Shorer Arbel Y, Scarfò L, Joffe E, Perry C, Ghia P. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165-3173.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 492]  [Cited by in F6Publishing: 465]  [Article Influence: 155.0]  [Reference Citation Analysis (0)]
15.  Terpos E, Trougakos IP, Gavriatopoulou M, Papassotiriou I, Sklirou AD, Ntanasis-Stathopoulos I, Papanagnou ED, Fotiou D, Kastritis E, Dimopoulos MA. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose. Blood. 2021;137:3674-3676.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 97]  [Cited by in F6Publishing: 115]  [Article Influence: 38.3]  [Reference Citation Analysis (0)]
16.  Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Terpos E, Dimopoulos MA. SARS-CoV-2 Vaccines in Patients With Multiple Myeloma. Hemasphere. 2021;5:e547.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 25]  [Cited by in F6Publishing: 24]  [Article Influence: 8.0]  [Reference Citation Analysis (0)]
17.  Li W, Wang D, Guo J, Yuan G, Yang Z, Gale RP, You Y, Chen Z, Chen S, Wan C, Zhu X, Chang W, Sheng L, Cheng H, Zhang Y, Li Q, Qin J; Hubei Anti-Cancer Association, Meng L, Jiang Q. COVID-19 in persons with chronic myeloid leukaemia. Leukemia. 2020;34:1799-1804.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 49]  [Cited by in F6Publishing: 70]  [Article Influence: 17.5]  [Reference Citation Analysis (0)]
18.  García-Suárez J, de la Cruz J, Cedillo Á, Llamas P, Duarte R, Jiménez-Yuste V, Hernández-Rivas JÁ, Gil-Manso R, Kwon M, Sánchez-Godoy P, Martínez-Barranco P, Colás-Lahuerta B, Herrera P, Benito-Parra L, Alegre A, Velasco A, Matilla A, Aláez-Usón MC, Martos-Martínez R, Martínez-Chamorro C, Susana-Quiroz K, Del Campo JF, de la Fuente A, Herráez R, Pascual A, Gómez E, Pérez-Oteyza J, Ruiz E, Alonso A, González-Medina J, Martín-Buitrago LN, Canales M, González-Gascón I, Vicente-Ayuso MC, Valenciano S, Roa MG, Monteliu PE, López-Jiménez J, Escobar CE, Ortiz-Martín J, Diez-Martin JL, Martinez-Lopez J; Asociación Madrileña de Hematología y Hemoterapia (AMHH). Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020;13:133.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 143]  [Cited by in F6Publishing: 150]  [Article Influence: 37.5]  [Reference Citation Analysis (0)]
19.  Percival MM, Lynch RC, Halpern AB, Shadman M, Cassaday RD, Ujjani C, Shustov A, Tseng YD, Liu C, Pergam S, Libby EN, Scott BL, Smith SD, Green DJ, Gopal AK, Cowan AJ. Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy. JCO Oncol Pract. 2020;16:571-578.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 14]  [Cited by in F6Publishing: 17]  [Article Influence: 4.3]  [Reference Citation Analysis (0)]